论文部分内容阅读
肺癌作为高发的恶性肿瘤之一,近十年发病率已占恶性肿瘤的首位,并且多数患者确诊时已处于中晚期,因此,化疗在肺癌的治疗中发挥了重要作用。但在临床工作中,经常遇到多数肺癌患者初治效果欠佳或者初治阶段效果较好,但经过多次治疗很难达到理想效果的情况,通过一系列研究表明这是因为肺癌存在多药耐药性(multidrug resistance,MDR)。因此研究肺癌多药耐药机制成为肺癌研究领域的热点,本文将就肺癌多药耐药机制研究的现状作一简单综述。
As one of the high-risk malignant tumors, the incidence of lung cancer has occupied the top of malignant tumors in recent ten years and most of the patients are in the advanced stage of diagnosis. Therefore, chemotherapy plays an important role in the treatment of lung cancer. However, in clinical work, most patients with lung cancer often encounter poor initial treatment or initial stage of better results, but after repeated treatment is difficult to achieve the desired effect of a series of studies have shown that this is because there is multi-drug lung cancer Multidrug resistance (MDR). Therefore, the study of lung cancer multi-drug resistance mechanism has become a hot area of lung cancer research, this article will be a brief overview of the current status of lung cancer multidrug resistance mechanism.